Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ovarian adenocarcinoma amplified long non-coding RNA (OVAAL)
- Target
- OVAAL
- Molecular classification
- Long non-coding RNA (lncRNA), Non-coding RNA, RNA gene, Long intergenic non-protein coding RNA
01
Overview
Ovarian adenocarcinoma amplified long non-coding RNA (OVAAL) is a long non-coding RNA gene (also referenced as LINC01131, OVAL, RMEL2) located on chromosome 1. It is classified as a lncRNA, with expression amplified in ovarian adenocarcinoma and restricted expression in melanoma. OVAAL participates in regulating gene expression, possibly through chromatin modification or RNA-mediated mechanisms, and is implicated in cancer cell proliferation and tumorigenesis in ovarian cancer and potentially melanoma. While OVAAL is a candidate cancer biomarker, and may provide a new avenue for diagnostic or therapeutic development, no drugs are currently known to directly target OVAAL, and its mechanism in disease is an active area of research.
- Other names
- LINC01131OVALRMEL2Long intergenic non-protein coding RNA 1131Ovarian adenocarcinoma amplified lncRNARestricted expression in melanoma 2
02
Mechanism of action
Not specifically targeted by any drug; potential mechanisms would involve gene expression regulation at the transcriptional or post-transcriptional level. LncRNAs like OVAAL may act by modulating chromatin structure, mRNA stability, or protein interactions, but direct mechanisms remain to be characterized.
03
Biological functions
Regulation of gene expressionRegulation of tumorigenesis and cancer cell biologyMay play a role in cell proliferationMay play a role in oncogenesis
04
Disease associations
Cancer (implicated in ovarian cancer and melanoma, with potential roles in tumorigenesis, prognosis or disease progression)Possible biomarker in ovarian cancerRestricted/high expression in melanoma
05
Safety considerations
None directly described, as OVAAL is not currently a drug target in clinical uselncRNA-targeted therapies, in general, face challenges in delivery, specificity, and potential off-target effects
06
Biomarkers
Potential biomarker for ovarian cancer diagnosisPotential biomarker for melanoma
Beyond the preview
Go deeper on Ovarian adenocarcinoma amplified long non-coding RNA (OVAAL).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ovarian adenocarcinoma amplified long non-coding RNA (OVAAL).